Retevmo 40 mg

$4,999.00

this product is available by prescription only

Clear Filters

Licensed partner pharmacies

Tracked international shipping

Refund within 28 days

Secure, encrypted checkout

First-in-Class RET Inhibitor — Weight-Based Lower-Dose Capsule

Retevmo 40 mg is the lower-dose capsule strength of selpercatinib, the first selective RET kinase inhibitor approved for RET-altered cancers. Designed for patients weighing less than 50 kg, it is used as part of a 120 mg twice-daily regimen — three 40 mg capsules per dose. Each capsule is manufactured to strict oncology pharmaceutical standards. Biomarker confirmation of a RET gene alteration via an approved companion diagnostic is required before initiating treatment.

Targeted Tumor Control with CNS Activity and Reduced Off-Target Toxicity

Retevmo blocks the oncogenic RET kinase — the mutant or fused protein driving tumor growth in RET-altered cancers. By selectively targeting RET rather than a broad range of kinases, it delivers meaningful antitumor activity with a more manageable side effect profile than earlier multikinase inhibitors. The compound also crosses the blood-brain barrier, providing clinically relevant activity against brain metastases — a significant benefit for patients with RET fusion-positive NSCLC and thyroid cancers prone to CNS spread.

120 mg Twice Daily for Patients Under 50 kg — Specialist Oversight Required

The recommended dose for patients weighing less than 50 kg is 120 mg twice daily — three 40 mg capsules per dose, taken with or without food. Capsules must be swallowed whole. Total daily dose is 240 mg. Dose modifications apply for drug interactions involving strong CYP3A4 inhibitors or inducers, hepatic impairment, and specific adverse reactions. Concurrent use of proton pump inhibitors or H2 blockers may reduce selpercatinib levels and should be managed per prescribing guidance. Treatment is initiated and overseen by an oncology specialist.

  • CAS:
  • Chemical Formula:
  • Molecular Weight:
  • Peptide Sequence:
  • Synonyms:

Frequently bought together

Related products

Order Retevmo 40 mg
Reliable Research-Grade Retevmo 40 mg Peptide with Verified Laboratory Quality

Buy Retevmo 40 mg

Precision Oncology Access Through a Trusted Canadian Supplier

Retevmo 40 mg is a critical component of the weight-based dosing strategy for selpercatinib. For patients under 50 kg, the 40 mg capsule makes it possible to achieve the 120 mg twice-daily target dose using three capsules per administration. This precision matters in oncology — where the right dose at the right level can make the difference between effective tumor control and unnecessary toxicity. The clinical evidence supporting Retevmo is grounded in the global LIBRETTO-001 trial, which demonstrated robust objective response rates in patients with RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. Patients in lower-weight cohorts were represented in this trial, supporting the clinical rationale for the weight-based dosing approach. For patients weighing 50 kg or more, Retevmo 80 mg is the appropriate strength — used at 160 mg twice daily. Both capsule strengths are available through Elivena. Oncology products on Elivena are supplied directly from Canadian sources with full product traceability. Elivena understands that access to precision oncology therapies must be fast, reliable, and professionally managed. Our account team can assist oncology providers and distributors with supply planning, documentation, and bulk ordering. Each order is packaged and shipped with the care that oncology medications demand. Treatment with Retevmo requires a confirmed RET alteration and specialist oversight throughout the course of therapy. Elivena supports healthcare providers in securing consistent, authenticated access to this important targeted therapy. Contact us today or place your order at elivena.com to ensure reliable access to Retevmo 40 mg for your patients or practice.

Frequently Asked Questions

What is Retevmo 40 mg used for?
Why is Retevmo dosed by body weight?
Does Retevmo work against brain metastases?
Is biomarker testing required before starting Retevmo?